News

Jan. 14 2014

Click here to read Accera's response to the recent FDA warning letter.

Jul. 18 2012

Accera, Inc., a privately held commercial-stage healthcare company focused on the discovery and development of innovative clinical applications to address acute and chronic neurodegenerative diseases, announced today a partnership with Nestlé Health Science. Although the terms of the transaction are not being disclosed, Nestlé Health Science will invest in Accera to further support clinical development and commercialization of Axona®, a prescription medical food intended for the clinical dietary management of the metabolic processes associated with mild to moderate Alzheimer’s Disease (AD). Luis Cantarell, President and CEO of Nestlé Health Science S.A., will join the company’s board of directors.

Jan. 03 2012

Accera, Inc., a privately held commercial-stage healthcare company focused on the discovery and development of innovative therapeutics to treat central nervous system disorders, announced today that Holger Kunze has been appointed to the position of Chief Executive Officer and as a member of the company’s Board of Directors (BoD). Concurrently, Sven Thormahlen, PhD, has also been appointed as a member of Accera’s BoD.

1 - 3 of 3

1